Editorial Perspectives On Decentralized Trials

31. The Right Precision Medicine Partner Is Essential For Trials And Patients 7/20/2021

    Patient recruitment is a challenge for all pharma and biotech companies. Despite the advances made in patient centricity and decentralized trials, the recruitment remains challenging. Part of the reason might be that the advent of precision medicine is paradoxically not making the recruitment challenge any easier.

32. A Drug Developer's First Experience With Decentralized Trials 7/1/2021

    When the FDA released new guidance for companies in May 2020, it seemed every drug developer was scrambling to convert its clinical trials to a decentralized approach. Advicenne was no exception. Robbie McCarthy, general manager, U.S. for Advicenne, hoped to determine how patients could participate in the trial without a mandatory hospital stay. That led to him seeking out CROs and technology service providers that offered a decentralized approach to trials.

33. DIA 2021 Promises Stellar Panels And An Improved Virtual Experience 5/7/2021

    The emergence of the COVID pandemic in 2019 hit a lot of organizations in the R&D and clinical space by surprise. The companies and organizations that convene stakeholders were no exception. One of those organizations was DIA. When shutdowns began to sweep across the globe in March, DIA’s Global Annual Meeting, which brings together thousands of attendees from around the world, was just 90 days away.

34. What Is Driving The Adoption Of EDC Applications? 3/19/2021

    In December 2020, Industry Standard Research (ISR) released the 4th edition of its EDC Market Dynamics and Service Provider Performance report. I spoke to Sherry Hubbard-Bednasz, market research director at ISR, for some insights into the report and its findings.

35. How To Be A Better Partner To Sites During A Pandemic 3/8/2021

    I interviewed a site professional to get her perspective on clinical trials in 2020, where we currently stand, and what she believes sponsor companies need to do if they truly want to become a sponsor of choice for clinical research sites. COVID brought a lot of challenges to the world of clinical research, but the industry is in a good position to incorporate change for all stakeholders.

36. UCB Uses Decentralized Trials To Manage Studies 2/16/2021

    UCB has a long history of conducting trials in immunology and neurology, with an emphasis in epilepsy. According to Tero Laulajainen, VP and head of global clinical science and operations for UCB, the company has a broad range of therapeutic expertise and numerous global trials, including studies in China. Therefore, the company expected to be impacted when news of the COVID-19 virus first began to make headlines. 

37. AI And Machine Learning Prepare Pharma For The Data Onslaught 1/29/2021

    When I reached out to several clinical executives in my network for their thoughts on trends that will impact trials in the coming year, the two mentioned most frequently were AI and decentralized trials.

38. Is AI Improving Outcomes In Clinical Trials? 1/21/2021

    In October 2020, I hosted a webinar on the topic of AI and how it will improve outcomes in clinical trials. This article highlights some of the comments from that discussion.

39. The Decentralized Trials & Research Alliance Hopes To Advance Studies 1/19/2021

    Amir Kalali and Craig Lipset spent a good portion of 2020 reaching out to pioneers in the clinical space who were working on decentralized trials. Conversations centered on what more could be done to scale their use. They worked together to create the Decentralized Trials & Research Alliance (DTRA) to accelerate the adoption of decentralized methodologies in research. 

40. Pandemic Accelerates The Evolution Of Clinical Trials 1/7/2021

    How much has the COVID-19 pandemic accelerated the evolution of clinical trials? A new report from Oracle Health Sciences and Informa Pharma Intelligence attempts to answer that question. The goal was to determine how the pandemic was changing clinical trial operations and identify the key challenges and opportunities surrounding those changes.